da Vinci surgical systems
Q2 2026 placements rose to 468 systems, up from 395 a year earlier, and the installed base reached 11,710.
The numbers
What it is
The da Vinci platform is the core robotic system that surgeons use for minimally invasive procedures in urology, gynecology, general surgery, thoracic and other specialties. Hospitals buy or lease the system, and its installed base generates instrument and service revenue on every case. Systems revenue is the placement-driven line that sets up future procedure volume.
Why it matters to the stock. Each new system placed adds a base that generates instrument and service revenue for years, so placements are a leading indicator for future procedure growth.
News
Intuitive sets 2026 da Vinci procedure growth guide at 13.5% to 15.5%
For full-year 2026, Intuitive expects da Vinci procedure growth of about 13.5% to 15.5%, with the company expecting to land closer to the midpoint.
Intuitive Q1 2026 revenue up 23% to $2.77 billion; raises 2026 procedure and margin guidance
Intuitive reported first-quarter 2026 revenue of $2.77 billion, up 23%, with non-GAAP EPS of $2.50 and GAAP EPS of $2.28.
Intuitive completes purchase of da Vinci and Ion distributors in Italy, Spain and Portugal
Intuitive completed its acquisition of the da Vinci and Ion distribution business run by ab medica, Abex and Excelencia Robótica.
Intuitive reports Q4 2025 revenue up 19% and guides 2026 da Vinci procedures 13% to 15%
Intuitive reported fourth-quarter 2025 revenue of $2.87 billion, up 19%, with non-GAAP EPS of $2.53 and GAAP EPS of $2.21.
Intuitive gives preliminary Q4 and full-year 2025 results ahead of JPMorgan conference
Intuitive released preliminary fourth-quarter and full-year 2025 figures on January 14, 2026, the day of its J.P.